SELLAS Life Sciences enters the second week of July in a different borrow regime than it occupied ten days ago — the acute squeeze pressure has partially unwound, but the underlying short conviction has not.
The borrow picture has shifted materially since the June 29 article flagged near-zero availability and a 149% cost to borrow. Availability has recovered from an almost fully depleted 0.04% to 7%, and cost to borrow has fallen from a peak of 193% on July 1 to 45.6% — still elevated by any normal standard, but less than a quarter of its crisis level. That partial easing suggests some shorts who were squeezed out have been replaced by new borrowers at lower rates, or that lenders have recycled shares back into the pool. The borrow market is no longer at maximum stress; it is tight but functional. Short interest itself, at 44.5% of free float on 63.4 million shares, has barely moved over the week — up just 0.5% — which means the broad short position is holding rather than unwinding.
Options positioning tells a more cautious story from a different angle. The put/call ratio has climbed to 0.39, now at its 52-week high and running more than two standard deviations above its 20-day average of 0.28. That is a meaningful shift: options traders, who were almost exclusively call-focused for most of May and June, have been steadily adding put exposure for the past two weeks. The move from a PCR of 0.16 in late May to 0.39 today is gradual but consistent — this is not a single day's hedging spike but a multi-week rotation toward downside protection. Combined with the stock's 8.5% drop on the week to $13.50, the options market appears to be pricing in more two-way risk than it did during the sharp June rally.
The stock's ORTEX short score of 91.6 places it in extreme territory across the universe, with a days-to-cover of 9.25 per official FINRA data. Factor scores reinforce the pressure: the short-score rank of 0 and utilization rank of 6 both place SLS near the very bottom of the distribution on lending-friendly conditions. The one genuine positive in the factor picture is momentum — SLS is still up 64% over the past month despite this week's pullback — but that same momentum is what attracted the heavy short base in the first place. Analyst coverage is thin and largely stale; Maxim Group raised its target to $10 in March 2026, well below the current price at $13.50, with the mean target across the limited coverage sitting at $27.50. Given the stock's history of extreme volatility and the gaps in analyst data, those targets carry limited informational weight.
The earnings calendar adds a near-term focal point: the next print is scheduled for August 10. Historical reactions have been volatile in both directions — a 24% one-day gain in May 2026, a 7% gain in another print, and a 0.9% loss in March 2026, with five-day moves ranging from -15.7% to +44.6%. Peers moved broadly lower this week: GALT fell 7.2% and LTRN dropped 12.3%, suggesting sector-wide weakness provided some additional headwind. NRIX was the exception, gaining 2.3%.
The question into August is whether the partial recovery in borrow availability holds or contracts again — and whether the growing put skew in options reflects a genuine directional shift or simply rational hedging ahead of a binary clinical-stage catalyst.
See the live data behind this article on ORTEX.
Open SLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
